Roundtable Discussion: Designing Flexible Trials to Withstand Changing Biomarker Expectations
- Identifying intermediate endpoints that could bridge the gap between early biomarker data and long-term clinical outcomes
- Evaluating the unique implications for rare disease programs where long-term outcomes are harder to measure
- Anticipating the impact of a move toward clinical outcome-based approvals on development timelines and investment strategies